Company Overview
Company Type: Private Company
Website: semathera.com
Number of Employees: -
Year Founded: 2016
Total Amount Raised (CAD mm)†: 2.59
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
SemaThera Inc., a biotechnology company, develops inhibitors of semaphorin 3A (SEMA3A) for the prevention and reversal of retinal vascular diseases. Its technology includes semaphorins, a family of proteins initially identified as axonal guidance molecules that direct neuronal growth cones during embryogenesis; semaphorin3A (SEMA3A) is synthesized as a disulphide-linked homodimer and dimerization is essential for signaling; semaphorins and diabetes; vascular permeability; retinal inflammation; and vascular regeneration. The company was founded in 2016 and is based in Westmount, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Cumberlidge, Garth 
President, CEO & Director
Sapieha, Przemyslaw 
Chief Scientific Officer
Clement, John 
Executive Vice President of Business Development

Key Board Members
Name
Title
Ranger, Maxime 
Chairman
Cumberlidge, Garth 
President, CEO & Director
Rafii, Mary Jane
Director


Primary Industry Classification
Biotechnology


Primary Office Location
4 Westmount square Suite 160 | Westmount, QC | H3Z 2S6 | Canada

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Amorchem
Mar-21-2018
Majority
-
Seed
Senju Pharmaceutical Co., Ltd.
Mar-21-2018
Minority
-
Seed


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Mar-21-2018
Mar-21-2018
Private Placement
Target
SemaThera Inc.
Amorchem,Senju Pharmaceutical Co., Ltd. Buyer Funds:AmorChem L.P.

2.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Mar-20-2023
Company Conference Presentations
SemaThera Inc. Presents at BIO-Europe Spring 2023, Mar-20-2023
May-14-2021
Strategic Alliances
Chiome Bioscience Inc. Announces Termination of Collaborative Development License and Exclusive Option Agreement for Anti-Semaphorin 3A Antibody
Mar-22-2021
Strategic Alliances
SemaThera Inc. Enters into A Research Collaboration and Exclusive License Agreement with Roche
Nov-01-2018
Executive/Board Changes - Other, Executive Changes - CEO
SemaThera Inc. Names Garth Cumberlidge as President & CEO
Mar-21-2018
Private Placements
SemaThera Inc. announced that it has received $2 million in funding from GeneChem, Senju Pharmaceutical Co.,Ltd.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Jul 09, 2018 05:54 AM
SemaThera Inc.
SemaThera, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 25, 2018 06:45 AM
SemaThera Inc.
SemaThera, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Mar 21, 2018 05:55 AM
SemaThera Inc.
SemaThera, Inc. - Company Report
Reports
7


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Ranger, Maxime 
Chairman
-
-
maxime@giiant.com
Cumberlidge, Garth 
President, CEO & Director
+1-508-423-1373
-
ceo@semathera.com
Rafii, Mary Jane
Director
-
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Cumberlidge, Garth 
President, CEO & Director
+1-508-423-1373
-
ceo@semathera.com
Sapieha, Przemyslaw 
Chief Scientific Officer
-
-
-
Clement, John 
Executive Vice President of Business Development
-
-
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
